Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Advanced Marker Discovery S L maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently features 2 pending office actions. These actions are distributed across 2 distinct examiners and 2 distinct art units. This distribution indicates that the company is active in multiple specialized areas within the biotechnology sector.
LU, CHENG is the busiest examiner for the portfolio, responsible for 1 pending office action. With 2 pending office actions total, the workload is divided among different examiners and art units. This variety in examiners suggests that the company's patent applications are being reviewed under different sets of expertise within the patent office.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LU, CHENG | 1 | 54.1% | +64.1% |
| FRITCHMAN, REBECCA M | 1 | 45.7% | +35.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16483714 | IN VITRO METHOD FOR THE DIAGNOSIS OF LUNG CANCER | FRITCHMAN, REBECCA M | 39d |
| 17434976 | PROTEIN SIGNATURE FOR THE DIAGNOSIS OF COLORECTAL CANCER AND/OR PRE-CANCEROUS STAGE THEREOF | LU, CHENG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16483714 | IN VITRO METHOD FOR THE DIAGNOSIS OF LUNG CANCER | FRITCHMAN, REBECCA M | 39d |
| 17434976 | PROTEIN SIGNATURE FOR THE DIAGNOSIS OF COLORECTAL CANCER AND/OR PRE-CANCEROUS STAGE THEREOF | LU, CHENG | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| 1758 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17434976 | PROTEIN SIGNATURE FOR THE DIAGNOSIS OF COLORECTAL CANCER AND/OR PRE-CANCEROUS STAGE THEREOF | LU, CHENG | 1642 | §101§103§112Other | Non-Final OA | — | Pending | Aug 30, 2021 |
| 16483714 | IN VITRO METHOD FOR THE DIAGNOSIS OF LUNG CANCER | FRITCHMAN, REBECCA M | 1758 | §101§103 | Non-Final OA | 39d | Pending | Aug 05, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial